ClinicalTrials.gg
CompletedNCT06867718COMO-1Updated May 28, 2026

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

A Phase 2 interventional study of RGT001-075 and Placebo Comparator in Obesity or Overweight, sponsored by Regor Pharmaceuticals Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Regor Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.

02

Conditions studied

  • Obesity or Overweight

Keywords

  • GLP-1 receptor agonist (GLP-1 RA)
  • Obesity
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 267 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Regor Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Male or female, age 18-75 years (inclusive) at the time of signing .
  2. (HbA1c) \<6.5% at screening.
  3. ≥30 kg/m².
  4. BMI ≥27 kg/m² and \<30 kg/m² with at least 1 weight-related comorbidity:

    • hypertension
    • dyslipidemia
    • cardiovascular (CV) disease
    • obstructive sleep apnea
  5. Have a stable body weight (\< 5% change) for the 3 months prior to randomization.

Exclusion Criteria (Obesity Related):

  1. Have obesity induced by other endocrine disorders (for example, Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).
  2. Have a prior or planned surgical treatment for obesity.
  3. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months before screening such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal liner.
  4. Have been treated with prescribed or OTC drugs or alternative remedies that promote weight loss within the last 3 months before screening.

Exclusion Criteria (Medical Conditions)

  1. Diabetes.
  2. Have a history of acute or chronic pancreatitis.
  3. Have current symptomatic gallbladder disease or biliary disease.
  4. Have known liver disease other than MASLD.
  5. Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma (MTC).
  6. Have a serum calcitonin ≥20 pg/mL.
  7. Have an \<30 mL/min/1.73 m², as determined by the central laboratory at screening.
  8. Have a history of Major Depressive Disorder (MDD) or other severe psychiatric disorders (e.g., schizophrenia or bipolar disorder) within the last 2 years.
  9. Have had any exposure to GLP-1 analogs, or other related compounds within the prior 3 months or any prior history of side effects from GLP-1 receptor agonist (GLP-1 RA) or other related compounds containing GLP-1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    RGT1

    Study Drug: RGT001-075 (Dose 1)

    Drug: RGT001-075

  • Experimental
    RGT2

    Study Drug: RGT001-075 (Dose 2)

    Drug: RGT001-075

  • Experimental
    RGT3

    Study Drug: RGT001-075 (Dose 3)

    Drug: RGT001-075

  • Experimental
    RGT4

    Study Drug: RGT001-075 (Dose 4)

    Drug: RGT001-075

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo Comparator

Interventions

  • RGT001-075 is a small molecule GLP-1 agonist

  • DrugPlacebo Comparator

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in body weight at Week 36

    Least Squares (LS) mean using mixed model repeated measures (MMRM)

    Time frame: Baseline and 36 weeks

Secondary outcomes

  1. Percent change from baseline in body weight at Week 26

    Least Squares (LS) mean using mixed model repeated measures (MMRM)

    Time frame: Baseline and 26 weeks

  2. Incidence of treatment emergent adverse events (TEAEs), TESAEs, TEAESIs overall

    To evaluate the safety and tolerability of RGT001-075 for weight loss in adults who are obese, or overweight with at least one weight-related comorbidity

    Time frame: Baseline through week 36

  3. Ambulatory Blood Pressure Monitoring (ABPM)

    The ABPM device will be attached to the nondominant arm, and participants will be instructed to wear the monitor for a 24- to 27-hour period.

    Time frame: Baseline, 26 weeks

  4. AUC0-last

    Area under the serum concentration curve from time-zero to the last quantifiable concentration of RGT001-075

    Time frame: week 15

  5. AUC0-inf

    Area under curve from time zero to time infinite

    Time frame: week 15

  6. Cmax

    Maximum concentration of RT001-075

    Time frame: week15

  7. Tmax

    Time to achieve maximum concentration of RT001-075

    Time frame: week 15

  8. t1/2

    Terminal half-life of RGT001-075

    Time frame: week 15

07

Study locations

35 sites
  • Alliance for Multispecialty Research, LLC
    Mobile, Alabama 36608, United States
  • Synexus Clinical Research
    Phoenix, Arizona 85020, United States
  • Velocity Clinical Research
    Huntington Park, California 90255, United States
  • Angels Clinical Research
    Doral, Florida 33122, United States
  • Optimal Research
    Melbourne, Florida 32934, United States
  • Angels Clinical Research
    Miami, Florida 33126, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014, United States
  • Synexus Clinical Research
    The Villages, Florida 32162, United States
  • Javara-Privia Medical Group, Georgia LLC
    Savannah, Georgia 31406, United States
  • Javara-Privia Medical Group, Georgia, LLC
    Thomasville, Georgia 31792, United States
  • Synexus Clinical Research
    Evansville, Indiana 47714, United States
  • Velocity Clinical Research
    Valparaiso, Indiana 46383, United States
  • Alliance for Multispecialty Research, LLC
    Lexington, Kentucky 40509, United States
  • Velocity Clinical Research
    Baton Rouge, Louisiana 70809, United States
  • Velocity Clinical Research
    Rockville, Maryland 20854, United States
  • Mankato Clinic-East Main Street-Javara
    Mankato, Minnesota 56001, United States
  • Synexus Clinical Research
    Richfield, Minnesota 55423, United States
  • Synexus Clinical Research
    Creve Coeur, Missouri 63141, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • Premier Health Research-Sparta-Objective Health
    Sparta, New Jersey 07871, United States
  • Velocity Clinical Research
    Vestal, New York 13850, United States
  • Javara-Tryon Medical Partners, PLLC
    Charlotte, North Carolina 28287, United States
  • Velocity Clinical Research
    Durham, North Carolina 27701, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45246, United States
  • Velocity Clinical Research
    Cleveland, Ohio 44122, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Velocity Clinical Research
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research
    Dallas, Texas 75230, United States
  • Synexus Clinical Research
    Dallas, Texas 75234, United States
  • Synexus Clinical Research
    San Antonio, Texas 78229, United States
  • Javara-Privia Medical Group Gulf Coast PLLC
    The Woodlands, Texas 77384, United States
  • Velocity Clinical Research
    Waco, Texas 76710, United States
  • Synexus Clinical Research
    Salt Lake City, Utah 84106, United States
  • Velocity Clinical Research
    West Jordan, Utah 84088, United States
  • Velocity Clinical Research
    Seattle, Washington 98105, United States
08

References and documents

Individual participant data

Plan to share: Undecided — The Sponsor recognizes that sharing anonymized data and other information from clinical trials can enhance biomedical research. The Sponsor is following ongoing discussions among industry, academia, and other stakeholders regarding data sharing. Industry and academic partners hold various positions on the amount, types, and forms of data that will be useful l to the research community, the public, and the process for sharing. As a small, young company, the Sponsor awaits further guidance and input from industry participants on best practices before issuing a comprehensive data sharing plan. For now, Sponsor defers a description of what data will be shared and the process for doing so.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Nov 2025, 9 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Mar 10, 2025
StartActual
Jan 24, 2025
Primary completionActual
Nov 6, 2025
CompletionActual
Nov 6, 2025
Results delay requested
May 26, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06867718
Lead sponsor
Regor Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Jan 24, 2025
Primary completion
Nov 6, 2025
Completion
Nov 6, 2025
Last update
May 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RGT001-075

Start the discussion